The high cost of CAR-T therapy has been a major barrier to its widespread adoption. However, a new study suggests that a more standardized, modular production approach could help to reduce costs and make this life-saving treatment more accessible to patients. The study, which was presented at theAdvanced Therapies Week in Miami, found that by adopting a production approach similar to that used by the car industry, CAR-T therapies could be manufactured more efficiently and at a lower cost.
The high cost of CAR-T therapy has been a major barrier to its widespread adoption. However, a new study suggests that a more standardized, modular production approach could help to reduce costs and make this life-saving treatment more accessible to patients. The study, which was presented at theAdvanced Therapies Week in Miami, found that by adopting a production approach similar to that used by the car industry, CAR-T therapies could be manufactured more efficiently and at a lower cost.